Gene: CHEK2 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs17886163
rs17886163
CHEK2
0.010 GeneticVariation BEFREE Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. 27595995

2016
dbSNP: rs200050883
rs200050883
CHEK2
0.010 GeneticVariation BEFREE Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. 27595995

2016
dbSNP: rs587780170
rs587780170
CHEK2
0.010 GeneticVariation BEFREE Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. 27595995

2016
dbSNP: rs778212685
rs778212685
CHEK2
0.010 GeneticVariation BEFREE CHEK2 truncating mutations (IVS2 + 1G>A or 1100delC) were identified in 9 of 1921 controls (0.5%) and in 11 of 690 (1.6%) unselected patients with prostate cancer [odds ratio (OR) = 3.4; P = 0.004]. 15087378

2004
dbSNP: rs786203472
rs786203472
CHEK2
0.010 GeneticVariation BEFREE CHEK2 truncating mutations (IVS2 + 1G>A or 1100delC) were identified in 9 of 1921 controls (0.5%) and in 11 of 690 (1.6%) unselected patients with prostate cancer [odds ratio (OR) = 3.4; P = 0.004]. 15087378

2004
dbSNP: rs863224748
rs863224748
CHEK2
0.010 GeneticVariation BEFREE CHEK2 truncating mutations (IVS2 + 1G>A or 1100delC) were identified in 9 of 1921 controls (0.5%) and in 11 of 690 (1.6%) unselected patients with prostate cancer [odds ratio (OR) = 3.4; P = 0.004]. 15087378

2004
dbSNP: rs17879961
rs17879961
CHEK2
0.030 GeneticVariation BEFREE Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate cancer. 17661168

2008
dbSNP: rs17879961
rs17879961
CHEK2
0.030 GeneticVariation BEFREE The missense variant I157T was also more frequent in men with prostate cancer (7.8%) than in controls (4.8%), but the relative risk was more modest (OR = 1.7; P = 0.03). 15087378

2004
dbSNP: rs17879961
rs17879961
CHEK2
0.030 GeneticVariation BEFREE The missense variant I157T was associated with an increased risk of breast cancer (OR 1.4; P=.02), colon cancer (OR 2.0; P=.001), kidney cancer (OR 2.1; P=.0006), prostate cancer (OR 1.7; P=.002), and thyroid cancer (OR 1.9; P=.04). 15492928

2004
dbSNP: rs587780194
rs587780194
CHEK2
0.700 GeneticVariation UNIPROT A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 25394175

2015
dbSNP: rs750984976
rs750984976
CHEK2
0.700 GeneticVariation UNIPROT A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 25394175

2015
dbSNP: rs77130927
rs77130927
CHEK2
0.700 GeneticVariation UNIPROT A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 25394175

2015
dbSNP: rs587780194
rs587780194
CHEK2
0.700 GeneticVariation UNIPROT Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? 24071797

2014
dbSNP: rs750984976
rs750984976
CHEK2
0.700 GeneticVariation UNIPROT Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? 24071797

2014
dbSNP: rs77130927
rs77130927
CHEK2
0.700 GeneticVariation UNIPROT Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? 24071797

2014
dbSNP: rs587780194
rs587780194
CHEK2
0.700 GeneticVariation UNIPROT Early detection of prostate cancer: AUA Guideline. 23659877

2013
dbSNP: rs750984976
rs750984976
CHEK2
0.700 GeneticVariation UNIPROT Early detection of prostate cancer: AUA Guideline. 23659877

2013
dbSNP: rs77130927
rs77130927
CHEK2
0.700 GeneticVariation UNIPROT Early detection of prostate cancer: AUA Guideline. 23659877

2013
dbSNP: rs587780194
rs587780194
CHEK2
0.700 GeneticVariation UNIPROT NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 22138009

2011
dbSNP: rs750984976
rs750984976
CHEK2
0.700 GeneticVariation UNIPROT NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 22138009

2011
dbSNP: rs77130927
rs77130927
CHEK2
0.700 GeneticVariation UNIPROT NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 22138009

2011
dbSNP: rs587780194
rs587780194
CHEK2
0.700 GeneticVariation UNIPROT National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 19042984

2008
dbSNP: rs750984976
rs750984976
CHEK2
0.700 GeneticVariation UNIPROT National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 19042984

2008
dbSNP: rs77130927
rs77130927
CHEK2
0.700 GeneticVariation UNIPROT National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 19042984

2008
dbSNP: rs121908698
rs121908698
CHEK2
T 0.700 CausalMutation CLINVAR